MedTrace Logo

Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease

NCT05362786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-08-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of intravenously delivered mesenchymal steml cells (MSC) in one of two fixed dosing regimens at two time points in patients with chronic kidney disease.

Conditions

  • Chronic Kidney Diseases

Interventions

DRUG

Allogeneic adipose-derived mesenchymal stem cells (MSC)

Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84

DRUG

Allogeneic adipose-derived mesenchymal stem cells (MSC)

Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0

Sponsors & Collaborators

  • LaTonya J. Hickson

    lead OTHER

Principal Investigators

  • LaTonya Hickson, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-07-24
Completion
2024-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362786 on ClinicalTrials.gov